Sana Biotechnology rises 6% as data from several studies will be released by year-end

seekingalpha08-10

Sana Biotechnology (NASDAQ:SANA) is up ~6% in Friday trading after announcing that it will release data on several key studies by the end of the year. One of the most anticipated is for UP421, an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2458851248?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1321240693/image_1321240693.jpg","is_english":true,"pubTime":"2024-08-10 02:00","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2458851248","market":"sg","top_or_hot":-1,"title":"Sana Biotechnology rises 6% as data from several studies will be released by year-end","media":"seekingalpha","content":"<div>\n<p>Sana Biotechnology (NASDAQ:SANA) is up ~6% in Friday trading after announcing that it will release data on several key studies by the end of the year. One of the most anticipated is for UP421, an ...</p>\n\n<a href=\"https://seekingalpha.com/news/4138287-sana-biotechnology-rises-6-data-several-studies-released-year-end\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sana Biotechnology rises 6% as data from several studies will be released by year-end</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSana Biotechnology rises 6% as data from several studies will be released by year-end\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-10 02:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4138287-sana-biotechnology-rises-6-data-several-studies-released-year-end><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sana Biotechnology (NASDAQ:SANA) is up ~6% in Friday trading after announcing that it will release data on several key studies by the end of the year. One of the most anticipated is for UP421, an ...</p>\n\n<a href=\"https://seekingalpha.com/news/4138287-sana-biotechnology-rises-6-data-several-studies-released-year-end\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SANA","symbol_name":"Sana Biotechnology, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4138287-sana-biotechnology-rises-6-data-several-studies-released-year-end","article_id":"2458851248","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1321240693/image_1321240693.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458851248","pubTimestamp":1723226443,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Sana Biotechnology  is up ~6% in Friday trading after announcing that it will release data on several key studies by the end of the year. One of the most anticipated is for UP421, an islet cell therapy for type 1 diabetes, an early-stage investigator sponsored trial. \"If proof-of-concept is achieved, we see potential for meaningful share appreciation,\" Citi analyst Samantha Semenkow, who rates the stock a buy, wrote in a note. \"Positive data would demonstrate feasibility in T1D while also providing encouraging readthrough to Sana's other hypoimmune assets.\" The biotech is also expected to release data from the phase 1 trial on SC291, a CD19-directed CAR T cell therapy which is under investigation for B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody -associated vasculitis. Sana anticipates data by the end of 2024 on another phase 1 trial for SC291 in B-cell malignancies. Also, phase 1 data is projected for SC262, a ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","BK4139":"生物科技"},"translate_title":"Sana Biotechnology股价上涨6%，多项研究数据将于年底公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SANA":1},"content_text":"Sana Biotechnology (NASDAQ:SANA) is up ~6% in Friday trading after announcing that it will release data on several key studies by the end of the year. One of the most anticipated is for UP421, an islet cell therapy for type 1 diabetes, an early-stage investigator sponsored trial. \"If proof-of-concept is achieved, we see potential for meaningful share appreciation,\" Citi analyst Samantha Semenkow, who rates the stock a buy, wrote in a note. \"Positive data would demonstrate feasibility in T1D while also providing encouraging readthrough to Sana's other hypoimmune assets.\" The biotech is also expected to release data from the phase 1 trial on SC291, a CD19-directed CAR T cell therapy which is under investigation for B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana anticipates data by the end of 2024 on another phase 1 trial for SC291 in B-cell malignancies. Also, phase 1 data is projected for SC262, a CD22-directed CAR T therapy, also for B-cell malignancies. Sana reported its Q2 financial results on Aug. 8.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458851248"}